0000899243-18-017794.txt : 20180622 0000899243-18-017794.hdr.sgml : 20180622 20180622211154 ACCESSION NUMBER: 0000899243-18-017794 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180620 FILED AS OF DATE: 20180622 DATE AS OF CHANGE: 20180622 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pomerantz Roger CENTRAL INDEX KEY: 0001614936 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37465 FILM NUMBER: 18915844 MAIL ADDRESS: STREET 1: 711 HARVEST HILL ROAD CITY: CHALFONT STATE: PA ZIP: 18914 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Seres Therapeutics, Inc. CENTRAL INDEX KEY: 0001609809 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274326290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617 945 9626 MAIL ADDRESS: STREET 1: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Seres Health, Inc. DATE OF NAME CHANGE: 20140603 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-06-20 0 0001609809 Seres Therapeutics, Inc. MCRB 0001614936 Pomerantz Roger C/O SERES THERAPEUTICS, INC. 200 SIDNEY STREET CAMBRIDGE MA 02139 1 1 0 0 President and CEO Common Stock 2018-06-20 4 S 0 26492 9.3255 D 297812 D Common Stock 2018-06-21 4 S 0 18987 9.0638 D 278825 D Common Stock 2018-06-22 4 S 0 40057 9.3557 D 238768 D The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.55. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.74. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Thomas J. DesRosier, Attorney-in-Fact 2018-06-22